PHARMACEUTICAL COMPOSITIONS AND METHODS
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
1 . A pharmaceutical composition comprising a tyrosine hydroxylase inhibitor; and melanin, a melanin promoter, or a combination thereof.
2 . The pharmaceutical composition of claim 1 wherein said tyrosine hydroxylase inhibitor is α-methyl-DL-tyrosine.
3 . The pharmaceutical composition of claim 1 comprising melanin.
4 . A pharmaceutical composition comprising a tyrosine hydroxylase inhibitor and a p450 3A4 promoter.
5 . The pharmaceutical composition of claim 4 wherein said tyrosine hydroxylase inhibitor is α-methyl-DL-tyrosine.
6 . The pharmaceutical composition of claim 4 wherein said p450 3A4 promoter is 5,5-diphenylhydantoin.
7 . A pharmaceutical composition comprising a tyrosine hydroxylase inhibitor and a leucine aminopeptidase inhibitor.
8 . The pharmaceutical composition of claim 7 wherein said tyrosine hydroxylase inhibitor is α-methyl-DL-tyrosine.
9 . The pharmaceutical composition of claim 7 wherein said leucine aminopeptidase inhibitor is rapamycin or N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine.
10 . A pharmaceutical composition comprising melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor.
11 . The pharmaceutical composition of claim 10 comprising melanotan II.
12 . The pharmaceutical composition of claim 10 wherein said p450 3A4 promoter is 5,5-diphenylhydantoin.
13 . The pharmaceutical composition of any one of claim 10 wherein said leucine aminopeptidase inhibitor is rapamycin or N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine.
14 . A kit comprising a pharmaceutical composition of claim 1 and a pharmaceutical composition according to claim 4 .
15 . The kit of claim 14 further comprising a pharmaceutical composition of claim 7 .
16 . The kit of claim 15 further comprising a pharmaceutical composition of claim 10 .
17 . The kit of claim 16 further comprising a pharmaceutical composition comprising a tyrosine hydroxylase inhibitor.
18 . A method for treating cancer comprising administering to a patient in need thereof a pharmaceutical composition of claim 1 , a pharmaceutical composition of claims 7 , a pharmaceutical composition of claim 10 , and a pharmaceutical composition comprising a tyrosine hydroxylase inhibitor.
19 . The method of claim 18 wherein said pharmaceutical compositions are administered to said patient within a 24 hour period.
20 . The method of claim 18 wherein said pharmaceutical compositions are administered to said patient five days per week for six weeks.